Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021 – Manchestertimes

Related Articles:

• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021 - Odessa American December 30, 2020 Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021  Odessa American
• Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021 - Business Wire December 30, 2020 Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021  Business Wire
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021 - Galveston County Daily News December 30, 2020 Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021  Galveston County Daily News
• Parkinson’s Forum Offers Patients and Caregivers Place to Learn, Share, and Foster Community August 23, 2019 Online forums have markedly altered how patients, caregivers, and healthcare professionals communicate and connect. Even when miles apart, individuals can establish supportive relationships, share experiences and information, and sometimes simply vent. BioNews Services, a leading online health, science and research publication company, has been rolling out its own forums, including one for Parkinson’s disease (PD), a progressive neurodegenerative disorder that affects…
• Davis Phinney Foundation at the 2019 Parkinson’s Policy Forum September 30, 2019 The Parkinson’s Policy Forum is an annual educational and advocacy event in Washington, DC for people with Parkinson’s and care advocates. The 2019 forum, held September 9-10, brought together over 150 people from 38 states to participate in a day of education and training followed by a day of visiting 196 Congressional offices. Sara Linn, Ambassador Leadership Program Manager for…
• If I Had A Billion Dollars April 12, 2019 “Perchik: Money is the world’s curse.Tevye: May the Lord smite me with it. And may I never recover.” –  Fiddler on the Roof   As I began receiving entries for the billion dollar contest over the last month, I started thinking about what I would have submitted. The whole contest has been an interesting thought experiment and it has helped me define what…
• Global Neurodegenerative Disorder Therapeutics Market 2019-2024: Opportunities in Digital Biomarkers, Microbiome Therapeutics, Cell and Gene Therapy, Drug Delivery, Drug Repurposing - ResearchAndMarkets.com - Manchestertimes October 14, 2019 Global Neurodegenerative Disorder Therapeutics Market 2019-2024: Opportunities in Digital Biomarkers, Microbiome Therapeutics, Cell and Gene Therapy, Drug Delivery, Drug Repurposing - ResearchAndMarkets.com  Manchestertimes
• Long-term effect of levodopa-carbidopa intestinal-gel on axial signs in Parkinson's disease. April 27, 2019 Related ArticlesLong-term effect of levodopa-carbidopa intestinal-gel on axial signs in Parkinson's disease. Acta Neurol Scand. 2019 Apr 26;: Authors: Fabbri M, Chatkaew P, Artusi CA, Romagnolo A, Rizzone MG, Zibetti M, Lopiano L Abstract BACKGROUND: few studies have suggested that levodopa-carbidopa intestinal gel (LCIG) may have a benefit on Parkinson's disease (PD) axial signs. AIMS OF THE STUDY: to investigate…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• The Wim Hof method February 6, 2020   A regular theme of the SoPD website is the reviewing of novel phamarcological treatments that are being tested on models of Parkinson’s. And while the breadth of the research is exciting and encouraging, the average reader may feel distant to the results of those studies as the experimental drug being tested is still a long way from possible regulatory…
• Pisa Syndrome Most Likely in Parkinson’s Patients with Axial Symptoms and Sleep Disorder, Study Says October 24, 2019 People with Parkinson’s disease are more likely to develop a disabling postural deformity known as Pisa syndrome if they have more severe axial symptoms — such as difficulty with speech or freezing of gait — and a sleep disorder known as rapid eye movement sleep behavior, a study suggests. The study, “Predictors of Pisa syndrome in Chinese patients with Parkinson’s…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• When Bluerock became Bayer August 18, 2019   Cell replacement therapy is a key component of any “cure” for Parkinson’s – replacing the cells that have been lost over the course of the condition. Cell transplantation of dopamine neurons has a long track record of both preclinical and clinical development and represents the most developed of the cell replacement approaches. Two weeks ago, the biotech firm BlueRock…
• 2019 Parkinson’s Policy Forum Drives Change on Access to Care Issues September 18, 2019 Last week, more than 150 Parkinson's disease (PD) advocates convened in Washington, D.C. for the 2019 Parkinson's Policy Forum. The Policy Forum brings people with PD and their loved ones to our nation's capital for a day of education and training followed by a day of advocacy with lawmakers on Capitol Hill. This year's Forum was co-sponsored by The Michael J. Fox Foundation (MJFF) and the Parkinson's Foundation. Ten other PD and…
• Collaborative Project Will Target Gut Metabolites Involved in Parkinson’s June 21, 2018 The Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics have launched a partnership to develop interventions targeting gastrointestinal metabolites that may fuel the development of Parkinson’s disease. Previous work by Axial’s scientific co-founder Sarkis Mazmanian, PhD, has shown that the human gut microbiome — the natural collection of microorganisms living in our guts — can amplify several features of Parkinson’s…
• Axial symptoms predict mortality in patients with Parkinson disease with subthalamic stimulation. May 3, 2019 Related ArticlesAxial symptoms predict mortality in patients with Parkinson disease with subthalamic stimulation. Neurology. 2019 May 01;: Authors: Lau B, Meier N, Serra G, Czernecki V, Schuepbach M, Navarro S, Cornu P, Grabli D, Agid Y, Vidailhet M, Karachi C, Welter ML Abstract OBJECTIVE: To characterize how disease progression is associated with mortality in a large cohort of patients with…
• ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease - Manchestertimes October 24, 2019 ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease  Manchestertimes
• Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy - Manchestertimes November 11, 2019 Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy  Manchestertimes